Apremilast, an oral phosphodiesterase inhibitor approved for moderated to severe psoriasis in adults, is the only novel oral medication that has been introduced to treat psoriasis in the past two decades. A new analysis supports the safety and cost-effectiveness of the agent, particularly those with less severe disease. (Expert Opin Drug Saf 2020 ePub) Authors conducted a review to assess the safety, efficacy, and adherence of apremilast for psoriasis treatment, finding it to be a safe and efficacious drug for moderate-to severe psoriasis. Despite numerous minor side effects, most patients adhere to therapy.